Hi!Back to the Top
I have noticed that there have been drug-interaction studies for almost
all different classes of antidiabetic compounds. The studies I have
difficulties to understand are those investigating possible
interactions between different classes of these compounds, when there
is (seemingly) no scientific rationale behind them. I am not aware of
any of these compounds being an inducer or inhibitor of enzymes
responsible for the metabolism of drugs from the other families of
antidiabetics. The same goes for possible PgP interactions.
So my question is: is there any reason/rationale for all drug-drug
interaction studies being done between different antidiabetics, or is
it just that people do it because it has always been done. It would be
interested to know what people at FDA think.
Back to the Top
I don't know what FDA thinks, but personally I believe that
It should be done so as to have a complete clinical profiling of a
drug. It applies to all drugs. It has been observed that even your
study protocol also have significant impact on clinical end point of
drug. So it's quite possible that some combination of therapy might
lead to adverse reactions.
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (email@example.com)